Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 8/20 | 0.48 |
| ▸ | PPARA | Q07869 | 8/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3972769 | 0.91 | PPARG (0.48) | PPARGPPARAPTPN1SMN1; SMN2PPARD | |
| SCHEMBL3978556 | 0.89 | PPARG (0.53) | PPARGPPARASMN1; SMN2LMNASLC6A9 | |
| SCHEMBL3972070 | 0.88 | PPARG (0.45) | PPARGPPARAPTPN1SMN1; SMN2LMNA | |
| Pemaglitazar SCHEMBL29908544 | 0.87 | PPARG (0.56) | PPARGPPARAPTPN1SLC6A9 | |
| Pemaglitazar SCHEMBL3971148 | 0.87 | PPARG (0.56) | PPARGPPARAPTPN1SLC6A9 | |
| Pemaglitazar SCHEMBL3971139 | 0.87 | PPARG (0.56) | PPARGPPARAPTPN1SLC6A9 | |
| Pemaglitazar SCHEMBL3971735 | 0.87 | PPARG (0.56) | PPARGPPARAPTPN1SLC6A9 | |
| SCHEMBL3979354 | 0.86 | PPARG (0.46) | PPARGPPARASMN1; SMN2LMNA | |
| SCHEMBL3972905 | 0.85 | PPARG (0.54) | PPARGPPARA | |
| Pemaglitazar SCHEMBL6904072 | 0.85 | PPARG (0.54) | PPARGPPARAPTPN1SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7556858-B2 | Substrate with attached dendrimers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2009-07-07 | — | — | US | disclosed |
| US-7491747-B2 | 4-(Arylthio)- or (4-heteroarylthio)butyric acid derivatives that may be used in the treatment of dyslipidaemia, atherosclerosis and diabetes | MERCK PATENT GMBH (DE) | 2009-02-17 | — | — | US | disclosed |
| US-20060068204-A1 | Substrate with attached dendrimers | 3M INNOVATIVE PROPERTIES COMPANY | 2006-03-30 | — | — | US | disclosed |
| US-20050020651-A1 | Butyric acid derivatives | MERCK PATENT GMBH (DE) | 2005-01-27 | — | — | US | disclosed |
| EP-1412326-A1 | BUTYRIC ACID DERIVATIVES | MERCK PATENT GmbH (DE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003011819-A1 | BUTYRIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020651-A1 | Butyric acid derivatives | GPR119, DBI, GABRB1 | PPARG 492/4885PPARA 425/4885PTPN1 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.